Drug Discovery And Development Europe Companies - Top Drug Discovery And Development Companies In Europe

Pharma Tech Outlook: Pharma Tech Magazine

NMS Group: The Prowess for Oncology Innovations

Top 10 Drug Discovery and Development Companies in Europe - 2021


Drugs discovered by the pharmaceutical industry over the past 100 years have dramatically changed the practice of medicine and impacted many aspects of culture. Traditionally, drug discovery relied on natural products as the primary source of new drug entities but was later shifted toward high-throughput synthesis and combinatorial chemistry-based development. New technologies such as ultra-high-throughput drug screening and artificial intelligence are heavily employed to reduce the cost and the time of early drug discovery, but they remain relatively unchanged. With the advent of modern molecular biology methods and based on knowledge of the human genome, drug discovery has now largely changed into a hypothesis-driven target-based approach. This development was paralleled by significant environmental changes in the pharmaceutical industry.

New paradigms in drug discovery and development rely on new technologies. These include DNA sequencers and a wide variety of new tools for gathering, analyzing, and disseminating genetic and genomic information. Advanced laboratories are now using robotics for automated screening to increase the overall speed of drug discovery. In addition, Magnetic Resonance Mass Spectrometry (MRMS) is a newfound instrument that provides an extra layer of confidence in screening for weak interactions of fragments. Further, major pharma companies have started adopting various strategies to integrate AI into their drug discovery process by hiring AI experts and data analysts. Several more pharma companies also implement machine learning-based deep learning technology to transform the small molecule research field and new biologics.

This edition of Pharma Tech Outlook brings you the companies providing cutting-edge drug discovery and development tech solutions and services. We hope the exhaustive information presented in the edition comes in handy for you to choose the right partner. In our selection, we looked at companies’ ability to identify client requirements, develop a strategic approach, and provide support and customization through their offerings.

We present to you Pharma Tech Outlook’s “Top 10 Drug Discovery and Development Companies in Europe - 2021.”

    Top Drug Discovery and Development Companies in Europe

  • Aelian Biotechnology combines CRISPR screening with single-cell sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes. The comppany utilizes the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next generation CRISPR screens. Its powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions of drugs. The Aelian team is composed of scientists from various countries. The company values different cultures and believes that diversity fosters creativity


  • DDR


    DDR is a European consultancy company that helps clients adhere to the regulations and guidelines imposed on them by the medical authorities


  • esqLABS is a digital life-sciences solutions company that leverages PBPK and QSP modeling and simulation approaches in the pharma, crop and chemical industry to help people achieve the best results with their new chemical or biologic entities.Specialising in modeling and simulation and personalised and translational medicine solutions, esqLABS is squarely focused on preclinical/clinical base PBPK model development, PBPK-based paediatric investigations and organ impairment studies, DDI investigations, and translational modeling for first-in-man dose predictions. esqLABS develops and utilises open source software to create physiologically-based Quantitative Systems Pharmacology (PB-QSP) platforms as value-generating, holistic modeling and simulation solutions to support customers’ decision-making process along the entire life cycle of pharmaceutical products, from research through development and at the point of care


  • On a mission to improve patients’ health through our unwavering commitment to discover, develop and deliver life-changing molecules


  • PCS


    PCS is a dedicated team of senior experts, each with 25 plus years' continuous hands-on experience and expertise in the field of preclinical drug development, including preclinical pharmacology, toxicology, toxicopathology, DMPK and GLP


  • Headquartered in Novara, Italy, Pharma Research Center (PRC) Ticinum Lab is an independent GMP and GLP authorised and FDA inspected contract laboratory. Since 2001, it offers high-level analytical services for Pharma companies, both API and Finished dosage forms, covering all the steps of the drug development—from discovery up to the post-market activities. The lab’s activities cover all the analytical aspects such as method development and validation, stability studies, impurity profile characterisation, genotoxic impurities evaluation, bioanalytical testing, interaction with packaging and leachable studies, as well as Batch Release testing both for synthetic and biotech drugs.


  • Acellera


    Acellera is a technology company focused on delivering services and solutions to companies and academic institutions on computing intensive, mission critical applications. By using Molecular Dynamics, Machine learning and exploiting the outstanding computational capabilities of new accelerator processors, Acellera help to achieve performances which would be otherwise unreachable using current standard technology

  • EsoCap


    A biotech company that cements its cornerstone around improving the lives of patients with serious illnesses through the development of a unique topical drug delivery platform for diseases of the esophagus

  • Cell4Pharma


    Cell4Pharma envision a world without a risk for renal toxicity for compounds entering clinical stages of drug development. Cell4Pharma aims to reduce the failure rate in late clinical stages due to renal tox below 3% market wide within the next 10 years. Without the use of animal experimentation. This ambition is supported by our human renal cell line ciPTEC validated during extensive collaborations with the pharmaceutical industry. More than 10 years of research lead to the development of robust cell-based assays focusing on the detection of highly specific biomarkers for renal toxicity

  • Collaborative Drug Discovery - CDD VAULT

    Collaborative Drug Discovery - CDD VAULT

    Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages private and external data. CDD VAULT lets its clients intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through and easy to use web interface. CDD Vault provides powerful structure-aware tools for chemists and screening data tools for biologists. Its shared system makes collaboration easy, and pipeline progress quicker